Combined citicoline and docosahexaenoic acid treatment improves cognitive dysfunction following transient brain ischemia. by Eri Nakazaki et al.
Combined citicoline and docosahexaenoic acid
treatment improves cognitive dysfunction
following transient brain ischemia.
著者 Eri Nakazaki, Yasushi Yabuki, Hisanao Izumi,
Yasuharu Shinoda, Fumiko Watanabe, Yukihiro
Hishida, Ayako Kamimura, Kohji Fukunaga
journal or
publication title







Creative Commons : 表示 - 非営利 - 改変禁止
http://creativecommons.org/licenses/by-nc-nd/3.0/deed.ja
ble at ScienceDirect
Journal of Pharmacological Sciences 139 (2019) 319e324Contents lists availaJournal of Pharmacological Sciences
journal homepage: www.elsevier .com/locate/ jphsFull PaperCombined citicoline and docosahexaenoic acid treatment improves
cognitive dysfunction following transient brain ischemia
Eri Nakazaki a, 1, Yasushi Yabuki b, 1, Hisanao Izumi b, Yasuharu Shinoda b,
Fumiko Watanabe a, Yukihiro Hishida a, Ayako Kamimura a, Kohji Fukunaga b, *
a Research & Innovation Center, Kyowa Hakko Bio Co., Ltd., Tsukuba, Ibaraki, 305-0841, Japan
b Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, 980-8678, Japana r t i c l e i n f o
Article history:
Received 13 July 2018
Received in revised form
8 February 2019
Accepted 12 February 2019




Bilateral common carotid artery occlusion
Neuroprotection
Memory* Corresponding author. Department of Pharma
Pharmaceutical Sciences, Tohoku University, Aram
Miyagi 980-8578, Japan.
E-mail address: kfukunaga@m.tohoku.ac.jp (K. Fuk
Peer review under responsibility of Japanese Pha
1 These authors contributed equally to this work.
https://doi.org/10.1016/j.jphs.2019.02.003
1347-8613/© 2019 The Authors. Production and hostin
license (http://creativecommons.org/licenses/by-nc-na b s t r a c t
Phospholipids are structural components of cellular membranes that play important roles as precursors
for various signaling pathways in modulating neuronal membrane function and maintenance of the
intracellular environment. Phosphatidylcholine (PtdCho) is the most abundant cellular phospholipid.
Citicoline and docosahexaenoic acid (DHA) are essential intermediates in the synthesis of PtdCho. Both
PtdCho intermediates have independently shown neuroprotective effects in cerebral ischemia, but their
combined effect is unknown. This study aimed to investigate the combined effect of oral citicoline and
DHA treatment on improvement of cognitive deficits following cerebral ischemia using a 20-min bilateral
common carotid artery occlusion (BCCAO) mouse model. BCCAO ischemic mice were treated for a total of
11 days with a combination of citicoline (40 mg/kg body weight/day) and DHA (300 mg/kg body weight/
day) or each alone. Combined citicoline and DHA synergistically and significantly improved learning and
memory ability of ischemic mice compared with either alone. Further, citicoline and DHA treatment
significantly prevented neuronal cell death, and slightly increased DHA-containing PtdCho in the hip-
pocampus, albeit not significantly. Taken together, these findings suggest that combined citicoline and
DHA treatment may have synergistic benefits for partially improving memory deficits following transient
brain ischemia.
© 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Cerebral ischemia is a leading cause of long-term disability that
is associated with a high incidence of motor and cognitive
dysfunction.1 Approximately 23% of ischemic strokes are caused by
transient ischemic attacks (TIA),2 thus safe and effective therapy at
the subacute phase after TIA is necessary to prevent consecutive
brain damage.
Citicoline is a mononucleotide composed of cytosine, pyro-
phosphate, and choline, and an essential intermediate in the syn-
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d/4.0/).neuroprotective effects in several animal models of central nervous
system injury, including cerebral ischemia.3e5 Meanwhile in
humans, many clinical stroke trials have shown that citicoline is the
only drug with neuroprotective benefit. Consistently, pooled anal-
ysis has revealed an effect of oral citicoline in patients with
moderate-to-severe acute ischemic stroke, however its effect ap-
pears limited. Recently, a large randomized controlled trial study
(namely ICTUS) found similar global recovery between citicoline
and placebo groups,6 indicating that developing combinations of
agents that show synergistic benefit with citicoline is required to
enhance its limited effect in brain ischemia.
Post-ischemic progression and neuronal injury are regulated by
multiple mechanisms, such as excitatory neurotransmitter accu-
mulation, calcium overload, and free radical and fatty acid gener-
ation. In addition, citicoline acts at several levels of the ischemic
cascade to repair the brain by stabilizing membrane phospho-
lipids.7 During brain ischemia, membrane phospholipids are
degraded to fatty acids, which are key molecules of the ischemicnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
E. Nakazaki et al. / Journal of Pharmacological Sciences 139 (2019) 319e324320cascade.8 Indeed, Lopes-Coviella et al., reported that citicoline
(500 mg/kg body weight) administered orally to rats for 90 days
increased the amount of PtdCho in the frontoparietal cortex by
approximately 30%.9
Docosahexaenoic acid (22:6, DHA) is an essential poly-
unsaturated fatty acid that is enriched in neural membranes and
especially found in PtdCho, phosphatidylethanolamine, and other
brain membrane phosphatides. DHA is required for brain devel-
opment and plays an important role in brain function.10 Deficiency
of DHA in the brain has been implicated in cognitive decline. In rats,
DHA is reported to improve spatial cognitive deficits induced by
transient forebrain ischemia,11 suggesting that DHA in brain tissue
may act as an antioxidant against free radical generation.12 In ger-
bils, oral administration of DHA (300 mg/kg/day) for 28 days in-
creases brain PtdCho levels by 22% as well as synaptic protein
levels.13
Both precursors of PtdCho, citicoline and DHA, have a neuro-
protective and enhancing effect on PtdCho synthesis in the brain,
but their combined effect is still unknown. Hence, the aim of our
study was to investigate whether administering citicoline and DHA
has a synergistic effect on improving cognitive dysfunction,
neuronal cell death, and molecular changes in phospholipids in the
hippocampus of mice subjected to bilateral common carotid artery
occlusion (BCCAO).
2. Materials and methods
2.1. Animals
Ten-week-old male C57BL/6 mice were purchased from Crea
Japan (Yokohama, Japan) and group housed at a constant temper-
ature (23± 1 C) and humidity (55 ± 5%) with lights on from 9:00 to
21:00 and ad libitum access to food and water. After arrival, mice
were habituated to the environment for 1 week, and fed a labora-
tory commercial eicosapentaenoic acid (EPA)- and DHA-deficient
diet prepared by deleting fish oil from standard diet (F-1; Funa-
bashi Farm, Chiba, Japan). All experimental procedures using ani-
mals were approved by the Committee on Animal Experiments of
Tohoku University.
2.2. Experimental design, preparation of ischemic model, and
dietary treatment
After acclimation, mice were divided into six groups: sham-
control, sham-combination (DHA 300 mg/kg body
weightþ citicoline 40mg/kg bodyweight), BCCAO-control, BCCAO-
DHA (300 mg/kg body weight), BCCAO-citicoline (40 mg/kg body
weight), and BCCAO-combination (DHA 300 mg/kg body
weight þ citicoline 40 mg/kg body weight).
BCCAO mice were prepared by surgery, as described previ-
ously.14 Briefly, mice were anesthetized with 4% halothane and
maintained with 2% halothane (Takeda Chemical Industries Ltd,
Osaka, Japan), then bilateral common carotid arteries were
occluded for 20 min via a lateral neck incision. One day after sur-
gery, mice were orally treated daily by gavage at a constant volume
of 10 mL/kg for 11 consecutive days. To reach final treatment doses,
citicoline was dissolved in distilled water and DHA suspended in
0.5% (w/v) methyl cellulose, with both reagents mixed well before
every use. Citicoline was provided by Kyowa Hakko Bio (Cognizin®;
Tokyo, Japan), DHA was purchased as DHA-rich oil (DHA™-S;
Martek Biosciences Co., Columbia, MD, USA) containing 35.7% DHA.
Control mice were treated with distilled water as the vehicle. An-
imals were subjected to behavioral tests from least to most
stressful: Y-maze task test at 8 days after surgery, novel object
recognition at 8e9 days after surgery, and step-through passiveavoidance task at 10e11 days after surgery.15 During behavioral
tasks, animals were administered each reagent after the task. Oral
administration was performed by 11 days after surgery in all
groups. At 12 days after surgery, mice were sacrificed and brain
tissue dissected for further analysis.
2.3. Y-maze task
Spontaneous alteration in the Y-maze task was used to deter-
mine willingness to explore new environments and spatial refer-
ence memory. The Y-maze task was performed as described
previously16 (see also Supplementary Material). Alternations were
defined as entries into all three independent arms on consecutive
choices. Percentage of alternations was calculated as actual alter-
nations/maximum alternations  100, with the number of actual
alternations reflecting continuous time of entry to each of three
arms. Moreover, number of maximum alternations was the total
number of arms entered minus two. Total number of arms entered
during the session was also determined.
2.4. Novel object recognition task
The novel object recognition task was performed as described
previously17 but with small modifications (see Supplementary
Material). The novel object recognition task consisted of training
and retention trials. Discrimination of spatial novelty was assessed
by comparing differences between exploratory contact of novel and
familiar objects. Total number of contacts with both objects was
recorded to adjust for differences in total exploration contact.
2.5. Step-through passive avoidance task
The step-through passive avoidance task was performed as
described previously17 (see also Supplementary Material). The
step-through passive avoidance task consisted of training and
retention trials. Step-through latency was recorded at 300 s to
assess the level of retention.
2.6. Histopathological analysis
Neuronal cell death was evaluated by histopathological analysis
with propidium iodide (PI) at 12 days after ischemia. Histopatho-
logical analysis was performed as described previously17 (see also
Supplementary Material). Total number of viable cells from the left
and right hippocampus of each animal was calculated as an average
of two randomly chosen 500  500 mm areas from three different
slices. Cell viability was expressed as a percentage of average
number of viable cells from control animals. Position of the hip-
pocampal CA1 region was identified by Paxinos and Franklin
(2001).18
2.7. Western blotting analysis
After decapitation of mice, the brain was rapidly removed and
tissue from the dorsal hippocampus dissected, immediately frozen
in liquid nitrogen, and stored at 80 C until analysis. Western blot
analyses were performed as described previously16 (see also
Supplementary Material). Two antibodies were used: anti-Ca2þ/
calmodulin-dependent protein kinase II (CaMKII)-a (1:5,000)19 and
anti-b-tubulin (1:10,000) (SigmaeAldrich, St. Louis, MO, USA).
2.8. PtdCho analysis in hippocampus
After decapitation of mice, the brain was rapidly removed and
tissue from the dorsal hippocampus dissected, immediately frozen
E. Nakazaki et al. / Journal of Pharmacological Sciences 139 (2019) 319e324 321in liquid nitrogen, and stored at 80 C until analysis. For liquid
chromatographyeFourier transform type mass spectrometry
(LCeFTMS) analysis, tissue samples from three mice were used,
based on the results of the novel object recognition task. Frozen
hippocampus was crushed frozen 3-times (1,500 rpm, 10 sec) with
a metal corn and Multi-beads Shocker (Yasui Kikai, Osaka, Japan).
The sample was then mixed with methanol containing PtdCho
(16:0, D31-18:1; Avanti Polar Lipids, Alabaster, AL, USA) as the in-
ternal qualitative standard, and crushed frozen once (1,500 rpm,
10 min). After adding dichloromethane, the mixture was crushed
frozen once again (1,500 rpm, 10 min), and then centrifuged
(9,100 g, 5 min). The upper phase was resuspended in 10-times
volume of acetone and stored at 80 C until use for LCeFTMS.
LCeFTMS analysis was performed by Chemicals Evaluation and
Research Institute (Tokyo, Japan) using a UFLC XR system (Shi-
madzu, Tokyo, Japan) coupled with a LTQ Orbitrap XL (Thermo
Fisher Scientific, Waltham, MA, USA). Lipids were eluted from a
column (L-column 2 ODS Metal-free, 2  150 mm, Particle size
3 mm; Chemicals Evaluation and Research Institute) heated at 40 C
using mobile phase A (19.6 mM ammonium formate) and mobile
phase B (acetone) at a flow rate of 0.2 mL/min. Column effluent was
directed into the electrospray source. Full MS scan range was
300e1,200 m/z, and spectra were acquired automatically in data-
dependent top N5 scan mode (positive). Peak processing was per-
formed using Mzmine 2 (http://mzmine.sourceforge.net/, ver. 2).
Detected peaks had intensity >5,000, and were identified by their
lipid class and carbon:double carbon number by m/z score and MS/
MS spectra. Peak data are shown as area normalized by area of each
internal control.
2.9. Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM).
Statistical analysis was performed using IBM SPSS Statistics version
25.0 (SPSS Inc., Chicago, IL, USA). Significant differences were
determined by one-way analysis of variance (ANOVA) followed by
multi-group comparisons between each group, then sham-control
versus the other groups using Dunnett's multiple comparison test.
In addition significant differences were determined by one-way
analysis of variance (ANOVA) followed by multi-group compari-
sons between each BCCAO group, and BCCAO-control group versus
BCCAO-treatment groups using Dunnett's multiple comparison
test. For the novel object recognition test, Student's t-test was used
to compare novel and familiar objects. Two-tailed P values < 0.05
were considered statistically significant in all analyses.
3. Results
3.1. Combined citicoline and DHA treatment improves impaired
memory-related behavior in BCCAO mice
We determined whether orally-administrated citicoline (40 mg/
kg) and DHA (300 mg/kg), either alone or in combination, improve
memory impairment observed in BCCAO mice. Dosage of citicoline
and DHAwas determined according to a preliminary trial (data not
shown), ineffective dosage of citicoline and DHA were chosen to
clarify their combined effect. The Y-maze task assesses the will-
ingness of mice to explore new environments and spatial working
memory. Percentage of alterations in behavior significantly
decreased in BCCAO-control mice compared with sham-control
mice (P < 0.05; Fig. 1A) without any change in total number of
arm entries (Fig. 1B). Treatment with DHA (300 mg/kg) to BCCAO
mice significantly improved alteration behavior compared with
BCCAO-control mice (P < 0.05; Fig. 1A) without any change in total
number of arm entries (Fig. 1B). Percentage of alteration behaviorwith combined citicoline and DHA was higher compared with
BCCAO-control mice, but no significant difference was observed
(P ¼ 0.117; Fig. 1A).
The novel object recognition task assesses recognition memory.
In the training session, no difference was observed in discrimina-
tion index using the same object in all animal groups (Fig. 1C). After
a 24 h retention interval between the training and test session,
sham-control mice showed a significantly higher discrimination
index for the novel object (P < 0.01; Fig. 1D). In contrast, BCCAO-
control mice failed to discriminate between familiar and novel
objects (Fig. 1D). This indicates that BCCAO mice show typical
memory impairment behavior. Under the same conditions, BCCAO
mice treated with a combination of citicoline and DHA showed a
significantly higher discrimination index for the novel object
(P < 0.01; Fig. 1D). While with DHA or citicoline treatment alone,
mice failed to discriminate between familiar and novel objects
(Fig. 1D).
The fear-conditioned passive avoidance task assesses contextual
memory. In the conditioning training session, no significant dif-
ferences were observed in any group in latency time to enter a dark
compartment (Fig. 1E). However, latency time to entering a dark
compartment was significantly decreased by 24 h after electric foot
shock in BCCAO-control mice compared with sham-control mice
(P < 0.05; Fig. 1F). This indicates that BCCAO mice show typical
memory impairment behavior. Treatment with a combination of
citicoline and DHA significantly restored the reduction in latency
time compared with BCCAO-control mice (P < 0.05; Fig. 1F).
Treatment with DHA or citicoline alone significantly decreased la-
tency time compared with sham-control mice (P < 0.01), and
showed no restoration of reduction in latency time compared with
BCCAO-control mice (Fig. 1F).
These findings indicate that a combination of citicoline and DHA
treatment has a synergistic ability to improve contextual memory
and recognition memory deficits in BCCAO ischemia-induced mice,
but not sham-treated mice.
3.2. Delayed neuronal cell death following BCCAO ischemia is
prevented by combined citicoline and DHA treatment
Following staining with PI, viable cells were counted in the
hippocampal CA1 region at 12 days after BCCAO ischemia to
examine neuroprotective effects. As previously reported,17 cell
viability significantly decreased in BCCAO-control mice compared
with sham-control mice (P < 0.01; Fig. 2A,B). Combined citicoline
and DHA treatment prevented neuronal cell death induced by
BCCAO ischemia in the hippocampal CA1 region (P < 0.01;
Fig. 2A,B). Although treatment with either DHA or citicoline alone
significantly decreased cell viability compared with sham-control
mice (P < 0.01), with no restoration of delayed neuronal cell
death compared with BCCAO-control mice (Fig. 2A,B). These find-
ings indicate that a combination of citicoline and DHA treatment
has a neuroprotective effect on BCCAO ischemia.
3.3. DHA treatment restores reduced CaMKIIa expression in the
hippocampal CA1 region of BCCAO mice
CaMKIIa is predominantly expressed in neurons,20 and CaMKIIa
(CaMKIIa) was significantly decreased in the hippocampal CA1
region after BCCAO ischemia (P < 0.01; Fig. 3A,B). In Fig. 3A, CaM-
KIIa was detected at 50 kDa using antibodies against CaMKIIa, but
non-specific bands were also observed at 60 kDa, which appear to
be CaMKIIb, g and/or d, because CaMKIIa shows high homology
with these three proteins. Unexpectedly, treatment with a combi-
nation of citicoline and DHA showed an increase in CaMKIIa, albeit
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Fig. 1. Effect of combined citicoline and docosahexaenoic acid treatment on impaired memory-related behavior following BCCAO ischemia. Alternation (A) or total arm entry
(B) in the Y-maze task. Number of objects in the trial session (C) or trial session (D) of the novel object recognition task. Latency time in the training session (E) or test session (F) of
the passive avoidance task. All data represent mean ± S.E. (n ¼ 6e8 per group). *P < 0.05, vs. sham-control; **P < 0.01, vs. sham-control; #P < 0.05, vs. BCCAO-control; yP < 0.01 vs.
familiar group. BCCAO, bilateral common carotid artery occlusion.
E. Nakazaki et al. / Journal of Pharmacological Sciences 139 (2019) 319e324322(P ¼ 0.119; Fig. 3A,B). Decreased CaMKIIa protein following BCCAO
ischemia was significantly restored by DHA (P < 0.05; Fig. 3A,B).
3.4. Molecular changes of PtdCho in the hippocampus of BCCAO
mice by combined citicoline and DHA treatment
It remains unclear whether citicoline and DHA treatment in
combination or alone can alter molecular species of PtdCho in the
hippocampus of BCCAO mice. Approximately 1,000 peaks were
detected, and 28 PtdCho species distributed in all groups were
identified by LCeFTMS analysis (Supplementary Material). Miya-
waki et al., reported 10 PtdCho species abundant in rat hippo-
campus, specifically, deacyl-16:0/16:0, deacyl-16:0/16:1, deacyl-16:0/18:1, deacyl-18:0/18:1, deacyl-16:0/20:4, deacyl-18:0/20:4,
deacyl-18:1/20:4, deacyl-16:0/22:6, deacyl-18:0/22:6, and deacyl-
18:1/22:6.21 We assumed that PtdCho with 4 double carbons is
arachidonic acid (AA) (20:4) containing PtdCho, and PtdCho with
6 double carbons is DHA containing PtdCho. Fig. 4 shows the ratio
of DHA-containing PtdCho (DHA-PtdCho) and AA-containing
PtdCho (AA-PtdCho). There were no significant differences
observed following ischemia, but as expected the ratio of DHA-
PtdCho/AA-PtdCho was higher in the hippocampus after com-
bined citicoline and DHA treatment (BCCAO-control, 0.53 ± 0.016;
BCCAO-combination, 0.56 ± 0.006), interestingly over DHA alone
(BCCAO-DHA; 0.54 ± 0.010) (Fig. 4; mean ± S.E.). In addition,
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Fig. 2. Neuroprotective effect of combined citicoline and docosahexaenoic acid
treatment against delayed neuronal cell death after transient BCCAO ischemia.
(A) Representative histological sections of the hippocampus. (B) Cell viability is
expressed as percentage of average number of viable cells from control mice. All data
in cell viability represent mean ± S.E. (n ¼ 4e6 per group). **P < 0.01, vs. sham-control;
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Fig. 3. Effect on CaMKII protein levels after transient BCCAO ischemia. (A) Repre-
sentative western blots of CaMKIIa and b-tubulin in the hippocampal CA1 region. (B)
Quantitative protein analysis of CaMKIIa. Blots of b-tubulin indicate equal protein
loading in each lane. All quantitative protein analysis data represent mean ± S.E. (n ¼ 6
per group). **P < 0.01, vs. sham-control; #P < 0.05, vs. BCCAO-control. BCCAO, bilateral
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Fig. 4. Molecular changes in PtdCho by treatment of citicoline, DHA, and their
combination. Peak area ratio of docosahexaenoic acid (DHA)-phosphatidylcholine
(PtdCho) and arachidonic acid (AA)-PtdCho in the hippocampus. *P < 0.05, vs. sham-
control. All data represent mean ± S.E. (n ¼ 3 per group).
E. Nakazaki et al. / Journal of Pharmacological Sciences 139 (2019) 319e324 323ratio of DHA-PtdCho/AA-PtdCho in BCCAO-mice compared with
sham-control mice (P < 0.05).
4. Discussion
Although we have shown that a combination of citicoline and
DHA treatment partially improves cognitive dysfunction in BCCAO
mice, its mechanism remains unclear. PtdCho reportedly decreases
due to activated membrane-bound phospholipase A2 in the brain,
which results from cerebral ischemic damage.8 Arachidonic acid is
released as free fatty acid from degraded phospholipids by phos-
pholipase A2, and accelerates inflammation due to eicosanoids
generated via an AA cascade. Thus, DHA is expected to suppress
hippocampal neuronal damage, and consequently be incorporated
into tissue and competitively inhibit AA, along with its own anti-
oxidant effect.12 Citicoline is widely used as an ischemic protective
agent, which stabilizes phospholipid metabolism.22 Moreover, cit-
icoline is demonstrated to inhibit activity of membrane-bound
phospholipase A2.23 From these reports, citicoline and DHA are
qualitatively and quantitatively effective treatments for cerebral
ischemia though PtdCho metabolism, which decreases during
ischemia. Considering mechanisms, it is tempting to speculate that
citicoline promotes uptake of DHA into brain tissue and synergis-
tically rescue BCCAO deficits.
We found that DHA-PtdCho in the hippocampus may syner-
gistically increase after combined citicoline and DHA treatment,
even though we did not identify a statistically significant difference
(Fig. 4). This suggests that citicoline can support incorporation of
DHA into brain tissue. Hippocampal PtdCho has recently been re-
ported to decrease once by 24 h after ischemia and recover after 7
days, suggesting that change in amount of molecular PtdCho spe-
cies is an apoptotic signal.21 Thus, it is possible that any change in
amount of PtdCho has already recovered by 12 days after ischemia,
which is the current sampling period. In addition, BCCAO mice
showed delayed neuronal cell death in the hippocampus (mainly
CA1 region), with a few affected neurons in other regions,24,25
whereas we used the entire hippocampus for LCeFTMS analysis.
Consideration of appropriate sampling time and brain region may
be needed to confirm these results.
A synergistic effect of citicoline and DHA treatment on the
benefit of learning and memory ability was not observed in the Y
maze task for working memory. For increased understanding on
combined citicoline and DHA treatment, we might identify
appropriate conditions, especially for intake dose, and change our
E. Nakazaki et al. / Journal of Pharmacological Sciences 139 (2019) 319e324324focus to the prefrontal cortex using a different ischemia model. For
example, in this study, BCCAO caused neuronal damage, particu-
larly to the hippocampal CA1 region (Fig. 2A). In animal studies,
working memory was originally used to explain hippocampal
function, however working memory is also controlled by the pre-
frontal cortex.26 DHA treatment to rat ischemia reduced infarct
volume mainly in cortical, and neuronal cell death, by modulating
the neuroinflammatory response.27 The effect of DHA to cortex
might in part account for improvement of working memory.
Alternatively, recovery of CaMKII levels and neuroprotection might
be contingent upon a balance in degree of ischemia and efficacy of
treatment. Yamamoto et al., reported that nobiletin partially pro-
tected neurons but failed to rescue CaMKII levels, because BCCAO
duration might affect consistent recovery of CaMKII levels and
neuroprotection.14 It may be needed further understandings on the
dynamic behavior of the recovery of CaMKII levels and neuro-
protection caused by BCCAO.
In conclusion, our results suggest that citicoline and DHA exert
synergistic activity for improving learning and memory ability by
preventing neuronal cell death following transient BCCAO
ischemia. Further, this effect may be related to PtdCho species,
especially DHA-containing PtdCho. More studies in another animal
model or clinically, need to be performed in the future to determine
the ability of DHA to enhance neuroprotection of citicoline.
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